Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.
about
Curated human hyperbilirubinemia data and the respective OATP1B1 and 1B3 inhibition predictionsObstetric Obesity is Associated with Neonatal Hyperbilirubinemia with High Prevalence in Native Hawaiians and Pacific Island Women.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools.Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models.Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.Evaluation and Comparison of the Inhibition Effect of Astragaloside IV and Aglycone Cycloastragenol on Various UDP-Glucuronosyltransferase (UGT) Isoforms.Diagnostic and predictive performance and standardized threshold of traditional biomarkers for drug-induced liver injury in rats.Regulation of Transporters and Channels by Membrane-Trafficking Complexes in Epithelial Cells.Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.Bioaccumulation and Subchronic Toxicity of 14 nm Gold Nanoparticles in Rats.Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins.Accurate identification of UDP-glucuronosyltransferase 1A1 (UGT1A1) inhibitors using UGT1A1-overexpressing HeLa cells.Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro.PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics
P2860
Q36292622-206E5653-4DC0-47D3-93E5-798D1488C906Q37488244-98B18AC6-60E9-4715-861A-51B6F46AFCE3Q37590883-2ACC0ADA-2535-4D3A-B777-548C7A0A06C6Q38192698-12988406-53A5-4353-942E-B482E1209EA7Q38827713-E16507F8-F88E-492D-86E6-3FF279F92988Q38927209-D0245F2A-ADE5-4FB8-B088-27ADA000F018Q39131985-7C60561C-2AC4-4FAD-B490-9FDD87B52962Q39135313-7DCA091C-A758-4DFC-960F-E947F9B901B6Q39155176-85DB706A-83C8-4085-BDBD-BCC2B6FB4FB6Q40684311-01E4ADC7-4243-4A6F-BC3D-DE28F7E756F1Q42091235-0AF4A809-35AC-467C-A77B-18EEE2970523Q46408497-399A2911-46C2-474A-BA30-719590B14575Q47895958-07B8910A-670E-437B-B73B-1DCB5DE0C315Q52937304-8C2B7577-45A9-464E-8D9D-C04264D363EBQ53232379-92A54145-8ACE-49B4-93CF-D9A74C6C34DBQ57403878-945EE76A-81EF-4A70-AB10-28EB5B27DA9B
P2860
Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Evaluating the in vitro inhibi ...... ug-induced hyperbilirubinemia.
@en
Evaluating the in vitro inhibi ...... ug-induced hyperbilirubinemia.
@nl
type
label
Evaluating the in vitro inhibi ...... ug-induced hyperbilirubinemia.
@en
Evaluating the in vitro inhibi ...... ug-induced hyperbilirubinemia.
@nl
prefLabel
Evaluating the in vitro inhibi ...... ug-induced hyperbilirubinemia.
@en
Evaluating the in vitro inhibi ...... ug-induced hyperbilirubinemia.
@nl
P2093
P356
P1476
Evaluating the in vitro inhibi ...... rug-induced hyperbilirubinemia
@en
P2093
Emile Plise
Jonathan Cheong
P304
P356
10.1021/MP4001348
P407
P50
P577
2013-06-21T00:00:00Z